NFE2L2 and non-small cell lung carcinoma: In NSCLC both HO-1 and TP, as well as Nrf2, are known to contribute to cell resistance to cisplatin, chemotherapeutic drug commonly used as a first-line treatment in clinic [12], [22], [32].